Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Reexamination Certificate
2009-06-30
2011-11-08
Robinson, Hope (Department: 1652)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
C424S094620, C435S375000, C435S019000
Reexamination Certificate
active
08052970
ABSTRACT:
The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase A2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus erythematosus.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4289872 (1981-09-01), Denkewalter et al.
patent: 4301144 (1981-11-01), Iwashita et al.
patent: 4496689 (1985-01-01), Mitra
patent: 4640835 (1987-02-01), Shimizu et al.
patent: 4670417 (1987-06-01), Iwasaki et al.
patent: 4791192 (1988-12-01), Nakagawa et al.
patent: 4861719 (1989-08-01), Miller
patent: 4892538 (1990-01-01), Aebischer et al.
patent: 5139941 (1992-08-01), Muzyczka et al.
patent: 5229490 (1993-07-01), Tam
patent: 5252479 (1993-10-01), Srivastava
patent: 5283187 (1994-02-01), Aebischer et al.
patent: 5328688 (1994-07-01), Roizman
patent: 5474935 (1995-12-01), Chatterjee et al.
patent: 5585362 (1996-12-01), Wilson et al.
patent: 5622856 (1997-04-01), Natsoulis
patent: 5658776 (1997-08-01), Flotte et al.
patent: 5661033 (1997-08-01), Ho et al.
patent: 5670488 (1997-09-01), Gregory et al.
patent: 5686278 (1997-11-01), Williams et al.
patent: 5693509 (1997-12-01), Cotten et al.
patent: 5707618 (1998-01-01), Armentano et al.
patent: 5770414 (1998-06-01), Gage et al.
patent: 5773289 (1998-06-01), Samulski et al.
patent: 5789390 (1998-08-01), Descamps et al.
patent: 5824544 (1998-10-01), Armentano et al.
patent: 5830725 (1998-11-01), Nolan et al.
patent: 5830727 (1998-11-01), Wang et al.
patent: 5834441 (1998-11-01), Philip et al.
patent: 5849571 (1998-12-01), Glorioso et al.
patent: 5851521 (1998-12-01), Branellec et al.
patent: 5856152 (1999-01-01), Wilson et al.
patent: 5863541 (1999-01-01), Samulski et al.
patent: 5879934 (1999-03-01), DeLuca
patent: 5888502 (1999-03-01), Guber et al.
patent: 7319015 (2008-01-01), Shayman et al.
patent: 7582442 (2009-09-01), Shayman et al.
patent: 0273085 (1988-07-01), None
patent: 0367566 (1990-05-01), None
patent: WO-91/18982 (1991-12-01), None
patent: WO-93/21259 (1993-10-01), None
patent: WO-93/25673 (1993-12-01), None
patent: WO-94/03564 (1994-02-01), None
Abe et al., “A novel enzyme that catalyzes the esterification of N-acetylsphingosine. Metabolism of C2-ceramides”,J. Biol. Chem., 271:14383-9 (1996).
Abe et al., “Lysosomal phospholipase A2 is selectively expressed in alveolar macrophages”,J. Biol. Chem., 279:42605-11 (2004).
Abe et al., “Positional specificity of lysosomal phospholipase A2”,J. Lipid Res., 47:2268-79 (2006).
Abe et al., “Purification and characterization of 1-O-acylceramide synthase, a novel phospholipase A2 with transacylase activity”,J. Biol. Chem., 273:8467-74 (1998).
Abe et al., “The acylation of lipophilic alcohols by lysosomal phospholipase A2”,J. Lipid Res., 48:2255-63 (2007).
Abe et al., “The secretion and uptake of lysosomal phospholipase A2 by alveolar macrophages”,J. Immunol., 181:7873-81 (2008).
Anderson, “Human gene therapy”,Nature, 392:25-30 (1998).
Ballas et al., “Liposomes bearing a quaternary ammonium detergent as an efficient vehicle for functional transfer of TMV-RNA into plant protoplasts”,Biochim. Biophys. Acta, 939:8-18 (1988).
Baumann et al., “Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus”,Arthritis Rheum., 46:191-201 (2002).
Behr et al., “Efficient gene transfer into mammalian primary endocrine cellwith lipopolyamine-coated DNA”,Proc. Natl. Acad. Sci. USA, 86:6982-6 (1989).
Behr et al., “Gene transfer with synthetic cationic amphiphiles: prospects for gene therapy”,Bioconjugate Chem., 5:382-9 (1994).
Behr, “DNA strongly binds to micelles and vesicles containing lipopolyamines or lipointercalants”,Tetrahedron Lett., 27:5861-4 (1986).
Benvenisty et al., “Direct introduction of genes into rats and expression of the genes”,Proc. Natl. Acad. Sci. USA, 83:9551-5 (1986).
Bombardier et al., “Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE”,Arthritis Rheum., 35:630-40 (1992).
Chen et al., “High-efficiency transformation of mammalian cells by plasmid DNA”,Mol. Cell Biol., 7:2745-52 (1987).
Cohen et al., “Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase”,J. Exp. Med., 196:135-40 (2002).
Cosman et al., “Cloning, sequence and expression of human interleukin-2 receptor”,Nature, 312:768-71 (1984).
Cosman et al., “High level stable expression of human interleukin-2 receptors in mouse cells generates only low affinity interleukin-2 binding sites”,Mol. Immunol., 23:935-41 (1986).
Dubensky et al., “Direct transfection of viral and plasmid DNA into the liver or spleen of mice”,Proc. Natl. Acad. Sci. USA, 81:7529-33 (1984).
Ehrenstein, “Antinuclear antibodies and lupus: causes and consequences”,Rheumatology(Oxford), 38:691-3 (1999).
Ellison et al., “The nucleotide sequence of a human immunoglobulin C gamma1 gene”,Nucleic Acids Res., 10:4071-9 (1982).
Englehard et al., “The insect tracheal system: a conduit for the systemic spread ofAutographa californicaM nuclear polyhedrosis virus”,Proc. Natl. Acad. Sci. USA, 91:3224-7 (1994).
Erwig et al., “Immunological consequences of apoptotic cell phagocytosis”,Am. J. Pathol., 171:2-8 (2007).
Fechheimer et al., “Transfection of mammalian cells with plasmid DNA by scrape loading and sonication loading”,Proc. Natl. Acad. Sci. USA, 84:8463-7 (1987).
Felgner et al., “Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure”,Proc. Natl. Acad. Sci. USA, 84:7413-7 (1987).
Felgner, “Improvements in cationic liposomes for in vivo gene transfer”,Hum. Gene Ther., 7:1791-3 (1996).
Felgner, “Nonviral strategies for gene therapy”,Sci. Am., 276:102-6 (1997).
Ferkol et al., “Regulation of the phosphoenolpyruvate carboxykinase/human factor IX gene introduced into the livers of adult rats by receptor-mediated gene transfer”,FASEB J., 7:1081-91 (1993).
Fraley et al., “Entrapment of a bacterial plasmid in phospholipid vesicles: potential for gene transfer”,Proc. Natl. Acad. Sci. USA, 76:3348-52 (1979).
Friedmann, “Progress toward human gene therapy”,Science, 244:1275-81 (1989).
Gopal, “Gene transfer method for transient gene expression, stable transformation, and cotransformation of suspension cell cultures”,Mol. Cell. Biol., 5:1188-90 (1985).
Graham et al., “A new technique for the assay of infectivity of human adenovirus 5 DNA”,Virology, 52:456-67 (1973).
Greenspan et al., “Idiotypes: structure and immunogenicity”,FASEB J., 7:437-44 (1993).
Greenwald et al., “Poly(ethylene glycol) conjugated drugs and prodrugs: a comprehensive review”,Crit. Rev. Ther. Drug Carrier Syst., 17:101-61 (2000).
Gronich et al., “Identification and characterization of a hormonally regulated form of phospholipase A2 in rat renal mesangial cells”,J. Biol. Chem., 263:16645-51 (1988).
Hanayama et al., “Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-deficient mice”,Science, 304:1147-50 (2004).
Hanayama et al., “MFG-E8-dependent clearance of apoptotic cells, and autoimmunity caused by its failure”,Curr. Dir. Autoimmun., 9:162-72 (2006).
Hargraves et al., “Presentation of two bone marrow elements; the tart cell and the L.E. cell”,Mayo Clin. Proc., 23:25-8 (1948).
Harland et al., “Translation of mRNA injected intoXenopusoocytes, specifically inhibited by antisense RNA”,J. Cell Biol., 10
Abe Akira
Kelly Robert
Kollmeyer Jessica
Lu Ye
Shayman James A.
Marshall & Gerstein & Borun LLP
Robinson Hope
The Regents of the University of Michigan
LandOfFree
Lysosomal phospholipase A2 (LPLA2) activity as a diagnostic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lysosomal phospholipase A2 (LPLA2) activity as a diagnostic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lysosomal phospholipase A2 (LPLA2) activity as a diagnostic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4283116